Patent ID: 11920200
Assignee: EUROFINS GENOMICS EUROPE SEQUENCING GMBH
Field: Medical technology (Instruments)
Classification: CPC C  G | IPC C  G

Claim 10:
11. A method of treating cancer in a human individual previously treated with carboplatin comprising: administering a chemotherapeutic agent to said human individual previously treated with carboplatin within about 3 months of said human individual having been determined to have a reduced response to a carboplatin therapy by a method comprising:
providing a serum or plasma sample from said human individual, said sample comprising cell-free DNA;
determining, in at least one molecule of said cell-free DNA, the methylation status at 16 CpGs located at positions 28, 31, 33, 45, 52, 58, 60, 62, 69, 104, 107, 110, 116, 121, 124 and 126 within the nucleotide sequence of SEQ ID NO: 2 or a 100% complementary sequence to said nucleotide sequence;
determining that said human individual will have a reduced response to carboplatin therapy when at least one molecule of said cell-free DNA is methylated at each of the 16 CpGs;
wherein: (a) when the human individual is a woman the cancer is selected from the group consisting of: breast cancer, lung squamous cell carcinoma, colon cancer, pancreatic cancer, uterine (endometrial) cancer, and ovarian cancer; or (b) when the human individual is a man the cancer is selected from the group consisting of: lung squamous cell carcinoma, colon cancer, pancreatic cancer and prostate cancer; and
wherein the chemotherapeutic agent is selected from the group consisting of: paclitaxel, docetaxel, cisplatin, liposomal doxorubicin, gemcitabine, trabectedin, etoposide, cyclophosphamide, an angiogenesis inhibitor and a PARP inhibitor.